Modality
Radioligand
MOA
SOS1i
Target
EZH2
Pathway
Wnt
Celiac
Development Pipeline
Preclinical
Oct 2023
→ Dec 2030
PreclinicalCurrent
NCT03265601
1,986 pts·Celiac
2023-10→2030-12·Completed
1,986 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-12-134.7y awayInterim· Celiac
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Complet…
Catalysts
Interim
2030-12-13 · 4.7y away
Celiac
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03265601 | Preclinical | Celiac | Completed | 1986 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 |